149 related articles for article (PubMed ID: 20569087)
1. Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.
Mukherji D; Pettengell R
Expert Opin Pharmacother; 2010 Aug; 11(11):1915-23. PubMed ID: 20569087
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.
Jamal-Hanjani M; Pettengell R
Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1441-8. PubMed ID: 21905966
[TBL] [Abstract][Full Text] [Related]
3. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
Pettengell R; Coiffier B; Narayanan G; de Mendoza FH; Digumarti R; Gomez H; Zinzani PL; Schiller G; Rizzieri D; Boland G; Cernohous P; Wang L; Kuepfer C; Gorbatchevsky I; Singer JW
Lancet Oncol; 2012 Jul; 13(7):696-706. PubMed ID: 22652183
[TBL] [Abstract][Full Text] [Related]
4. Pixantrone maleate for non-Hodgkin's lymphoma.
Mukherji D; Pettengell R
Drugs Today (Barc); 2009 Nov; 45(11):797-805. PubMed ID: 20126672
[TBL] [Abstract][Full Text] [Related]
5. The role of pixantrone in the treatment of non-Hodgkin's lymphoma.
Borchmann P; Schnell R
Expert Opin Investig Drugs; 2005 Aug; 14(8):1055-61. PubMed ID: 16050797
[TBL] [Abstract][Full Text] [Related]
6. Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma.
Boyle EM; Morschhauser F
Expert Opin Drug Saf; 2015 Apr; 14(4):601-7. PubMed ID: 25716061
[TBL] [Abstract][Full Text] [Related]
7. Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas.
El-Helw LM; Hancock BW
Expert Opin Investig Drugs; 2007 Oct; 16(10):1683-91. PubMed ID: 17922631
[TBL] [Abstract][Full Text] [Related]
8. Pixantrone: a promising drug in the treatment of non-Hodgkin lymphomas.
El-Helw LM; Hancock BW
Future Oncol; 2009 May; 5(4):445-53. PubMed ID: 19450173
[TBL] [Abstract][Full Text] [Related]
9. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.
Borchmann P; Morschhauser F; Parry A; Schnell R; Harousseau JL; Gisselbrecht C; Rudolph C; Wilhelm M; Günther H; Pfreundschuh DM; Camboni G; Engert A
Haematologica; 2003 Aug; 88(8):888-94. PubMed ID: 12935976
[TBL] [Abstract][Full Text] [Related]
10. Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper.
Zinzani PL; Corradini P; Martelli M; Minotti G; Oliva S; Spina M; Barosi G; Tura S
Eur J Haematol; 2016 Dec; 97(6):554-561. PubMed ID: 27124765
[TBL] [Abstract][Full Text] [Related]
11. The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's Lymphoma.
Muszbek N; Kadambi A; Lanitis T; Hatswell AJ; Patel D; Wang L; Singer JW; Pettengell R
Clin Ther; 2016 Mar; 38(3):503-15. PubMed ID: 26856929
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.
Hübel K
Expert Opin Pharmacother; 2018 Nov; 19(16):1829-1834. PubMed ID: 30269614
[TBL] [Abstract][Full Text] [Related]
13. Pixantrone: novel mode of action and clinical readouts.
Minotti G; Han H; Cattan V; Egorov A; Bertoni F
Expert Rev Hematol; 2018 Jul; 11(7):587-596. PubMed ID: 29912583
[TBL] [Abstract][Full Text] [Related]
14. Pixantrone: merging safety with efficacy.
Papadatos-Pastos D; Pettengell R
Expert Rev Hematol; 2013 Feb; 6(1):25-33. PubMed ID: 23373776
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.
Sancho JM; Navarro B; Soler Campos JA; de Oteyza JP; de Barrenetxea Lekue C; Bregni M; Grasso Cicala S; Spione M; Mombiedro C; Soler B; Zinzani PL
Eur J Haematol; 2020 May; 104(5):499-508. PubMed ID: 31997425
[TBL] [Abstract][Full Text] [Related]
16. Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.
Keating GM
Drugs; 2016 Oct; 76(16):1579-1586. PubMed ID: 27757832
[TBL] [Abstract][Full Text] [Related]
17. Galiximab: a review.
Bhat S; Czuczman MS
Expert Opin Biol Ther; 2010 Mar; 10(3):451-8. PubMed ID: 20092425
[TBL] [Abstract][Full Text] [Related]
18. The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use.
Péan E; Flores B; Hudson I; Sjöberg J; Dunder K; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
Oncologist; 2013; 18(5):625-33. PubMed ID: 23615696
[TBL] [Abstract][Full Text] [Related]
19. EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma.
Engert A; Herbrecht R; Santoro A; Zinzani PL; Gorbatchevsky I
Clin Lymphoma Myeloma; 2006 Sep; 7(2):152-4. PubMed ID: 17026830
[No Abstract] [Full Text] [Related]
20. Pixantrone beyond monotherapy: a review.
Barrenetxea Lekue C; Grasso Cicala S; Leppä S; Stauffer Larsen T; Herráez Rodríguez S; Alonso Caballero C; Jørgensen JM; Toldbod H; Leal Martínez I; D'Amore F
Ann Hematol; 2019 Sep; 98(9):2025-2033. PubMed ID: 31312929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
